And this summer, the Globe are adding something new to the Wild West canon with their riotous new production of Shakespeare’s most famous tragedy. In this version of the familiar story ...

Positive high-level results from the phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced today that its asthma treatment, Breztri Aerosphere, has met all primary endpoints in the Phase III KALOS and LOGOS trials. The trials demonstrated ...

WILMINGTON, Del. - AstraZeneca (Market cap: $219.79B), a prominent player in the pharmaceuticals industry with an "GREAT" financial health rating according to InvestingPro, announced its ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of annual sales of $3 billion to $5 billion for the 3-in-1 inhaler.

KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRI as a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRI ...

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE ...

KALOS and LOGOS trials with 4,400 patients showed Breztri improved lung function over dual ICS/LABA therapies. No new safety concerns were found in Breztri Phase 3 asthma trials; all primary ...

Breztri is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan.

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...

(Sharecast News) - AstraZeneca announced on Friday that its inhaled triple-combination therapy 'Breztri Aerosphere' met all primary endpoints in two phase three trials, delivering statistically ...